2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).
Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).
Currently, platnium-based treatments are being explored, but they are still a work in progress, says Carey. Studies are showing promise, but there is a lack of information to prove that their success translates into overall survival for patients.
The future of tailoring treatment, says Carey, is based on the effectiveness of biomarker development—including immune biomarkers. Also, non-cytotoxic options need to be included in the treatment landscape, as there are none currently available.
Related Content: